Contact
GBG Forschungs GmbH
Martin-Behaim-Straße 12
63263 Neu-Isenburg
Germany
Phone.: +49610274800
Fax: +4961027480440
E-Mail: Infgbgd
Contact form
News
23.10.2020 September 2020: Clinical Outcome of Breast Cancer Patients with asymptomatic brain metastases.
Analysis of breast cancer patients with asymptomatic brain metastases from BMBC registry has been published in Cancers (Basel).
Mehr ...23.10.2020 August 2020: MGMT promoter methylation in TNBC
A translational research project evaluating the MGMT promoter methylation status in TNBC from GeparSixto has been published in PLoSOne
Mehr ...09.10.2020 PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint
The collaborative Phase 3 PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival (iDFS) in women with hormone receptor-positive (HR+), human epidermal growth factor-negative (HER2-) early breast cancer (eBC) who have residual invasive disease after completing neoadjuvant chemotherapy. No unexpected safety signals were observed.
Mehr ...14.09.2020 GBG Research at ESMO Virtual Meeting 2020
Data of several GBG studies was presented at the upcoming ESMO Virtual Meeting 2020, which took place from 19 to 21 September 2020.
Mehr ...14.07.2020 July 2020: Tumor mutational burden and immune gene expression in GeparNuevo trial
A research project investigating tumor mutational burden and immune gene expression profile for response to neoadjuvant treatment in early TNBC has been published in Annals of Oncology
Mehr ...